BGLC

MKT CAP:$4M

BioNexus Gene Lab Corp.

Market Cap

$4M

Healthcare·Medical - Diagnostics & Research· Malaysia·NASDAQ

Healthcare·Medical·NASDAQ

Stock Price

$2.22-$1.72 (-43.65%)

Apr 22, 2026

Company Details

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material pro...

CEO

Su-Leng Tan

IPO Date

Jan 8, 2021

Website

www.bionexusgenelab.com

Key Metrics TTM

Revenue

$7M

-21.9% YoY

Net Income

-$3M

EPS (Diluted)

-$1.61

Free Cash Flow

-$2M

Revenue / Share

$4.00

Gross Margin

14.6%

Operating Margin

-39.9%

Net Margin

-40.2%

FCF Margin

-25.6%

P/S

0.6x

P/E

—

Earnings Reports

FY 2025

Apr 14, 2026

NEW

$7M-21.9%EPS -$1.61

Q4 2025

Apr 14, 2026

NEW

$483.8K-80.8%EPS -$0.53

Q3 2025

Nov 14, 2025

$3M-3.3%EPS -$0.39

Q2 2025

Aug 18, 2025

$2M+14.5%EPS -$0.34

Q1 2025

May 15, 2025

$2M-10.3%EPS -$0.35

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$3M	$333.5K	$34.7K
Q2 22	$2M	$243.3K	-$138.0K
Q3 22	$3M	$299.5K	-$65.2K
Q4 22	$3M	$339.2K	-$122.7K
Q1 23	$2M	$368.9K	-$50.6K
Q2 23	$3M	$339.7K	-$272.2K
Q3 23	$3M	$354.3K	-$3M
Q4 23	$2M	$266.6K	$256.7K
Q1 24	$2M	$365.0K	-$79.0K
Q2 24	$2M	$288.7K	$259.2K
Q3 24	$3M	$326.5K	-$1M
Q4 24	$3M	$309.2K	-$416.2K
Q1 25	$2M	$343.5K	-$618.4K
Q2 25	$2M	$368.0K	-$611.3K
Q3 25	$3M	$377.7K	-$702.5K
Q4 25	$483.8K	-$4.0K	-$1M

Valuation

Quarter	P/S	P/E
Q1 22	23.0x	693.3x
Q2 22	15.9x	746.6x
Q3 22	16.4x	—
Q4 22	15.9x	—
Q1 23	10.8x	—
Q2 23	6.8x	—
Q3 23	1.4x	—
Q4 23	0.9x	—
Q1 24	1.1x	—
Q2 24	0.9x	—
Q3 24	0.9x	—
Q4 24	0.5x	—
Q1 25	0.5x	—
Q2 25	0.6x	—
Q3 25	1.0x	—
Q4 25	1.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$37.8K	-$70.0K
Q2 22	-$187.7K	-$189.0K
Q3 22	$308.9K	$305.2K
Q4 22	$474.5K	$457.4K
Q1 23	-$116.5K	-$116.6K
Q2 23	-$23.8K	-$38.2K
Q3 23	-$899.3K	-$1M
Q4 23	-$261.9K	-$262.8K
Q1 24	-$37.2K	-$59.1K
Q2 24	-$672.3K	-$674.1K
Q3 24	-$1M	-$2M
Q4 24	-$54.3K	-$58.3K
Q1 25	-$824.1K	-$833.1K
Q2 25	-$737.9K	-$759.4K
Q3 25	-$1M	-$1M
Q4 25	$961.1K	$930.6K

Capital Expenditures

Quarter	CapEx
Q1 22	$32.2K
Q2 22	$1.3K
Q3 22	$3.7K
Q4 22	$17.0K
Q1 23	$102
Q2 23	$14.4K
Q3 23	$134.0K
Q4 23	$937
Q1 24	$21.9K
Q2 24	$1.8K
Q3 24	$199.2K
Q4 24	$4.0K
Q1 25	$9.1K
Q2 25	$21.5K
Q3 25	$5.5K
Q4 25	$30.5K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-12.2%	-3.6%
Q2 22	-19.6%	-11.1%
Q3 22	-28.0%	-17.6%
Q4 22	-12.5%	-2.7%
Q1 23	-21.5%	-18.9%
Q2 23	+3.3%	+8.2%
Q3 23	-0.8%	+92.5%
Q4 23	-20.0%	-31.9%
Q1 24	+0.2%	+1.4%
Q2 24	-23.1%	-39.6%
Q3 24	+3.0%	-21.9%
Q4 24	+11.0%	+45.8%
Q1 25	-10.3%	+12.0%
Q2 25	+14.5%	+67.4%
Q3 25	-3.3%	-18.2%
Q4 25	-80.8%	-48.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q3 22	$0	0.0%
Q4 22	$0	0.0%
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	-$89.0K	-3.9%
Q1 24	$0	0.0%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$794.8K	164.3%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	—	$345.2K	—
Q2 22	—	$434.1K	—
Q3 22	—	$418.8K	—
Q4 22	—	$487.9K	—
Q1 23	—	$536.9K	—
Q2 23	—	$807.1K	—
Q3 23	—	$3M	—
Q4 23	$55.0K	—	—
Q1 24	$11.5K	$315.8K	$153.9K
Q2 24	$8.2K	$759.7K	—
Q3 24	—	$2M	—
Q4 24	$47.5K	—	$2M
Q1 25	$12.1K	$391.9K	—
Q2 25	$12.6K	$516.8K	$608.4K
Q3 25	$14.9K	$445.7K	—
Q4 25	$11.1K	$975.9K	$35.6K

Revenue Segments

Quarter	Product And Service
Q2 25	$2M
Q3 25	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$2M	$0	$2M
Q2 22	$1M	$0	$1M
Q3 22	$1M	$0	$1M
Q4 22	$2M	$0	$2M
Q1 23	$2M	$0	$2M
Q2 23	$2M	$0	$2M
Q3 23	$6M	$0	$6M
Q4 23	$3M	$3M	$6M
Q1 24	$6M	$0	$6M
Q2 24	$5M	$0	$5M
Q3 24	$4M	$0	$4M
Q4 24	$4M	$0	$4M
Q1 25	$4M	$0	$4M
Q2 25	$814.2K	$2M	$3M
Q3 25	$3M	$0	$3M
Q4 25	$2M	$0	$2M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	1M	-0.0%	-0.0%
Q2 22	1M	+1.0%	+1.0%
Q3 22	1M	+0.4%	+1.5%
Q4 22	1M	0.0%	+1.4%
Q1 23	1M	0.0%	+1.5%
Q2 23	1M	0.0%	+0.4%
Q3 23	2M	+15.9%	+15.9%
Q4 23	2M	+5.3%	+22.0%
Q1 24	2M	0.0%	+22.0%
Q2 24	2M	0.0%	+22.0%
Q3 24	2M	+1.7%	+7.1%
Q4 24	2M	0.0%	+1.7%
Q1 25	2M	0.0%	+1.7%
Q2 25	2M	-0.0%	+1.7%
Q3 25	2M	0.0%	-0.0%
Q4 25	2M	+3.3%	+3.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$159.4K	19
Q2 22	$130.8K	19
Q3 22	$135.5K	19
Q4 22	$157.8K	18
Q1 23	$132.1K	18
Q2 23	$142.6K	18
Q3 23	$141.9K	18
Q4 23	$126.3K	18
Q1 24	$132.3K	18
Q2 24	$109.7K	18
Q3 24	$146.1K	18
Q4 24	$120.2K	21
Q1 25	$101.8K	21
Q2 25	$107.6K	21
Q3 25	$121.1K	21
Q4 25	$1	403K

Revenue / Employee